The ambition is expansive. The operating focus is not. NEUVIOR and PHARMORIS come first; future theses advance only when evidence earns the next gate.
An operating company and a controlled product-development programme. Neither stage is used as shorthand for deployment, customers or clinical outcomes.
The Scottish company through which Varun is building a focused medicines-systems thesis.
Present evidence
NEUVIOR Pharmaceuticals Ltd, incorporated in Scotland in 2025.
An operating company is not evidence of customers, deployment or clinical outcomes.
A staff-facing system intended to connect reviewable evidence, authorised decisions and accountable follow-through.
Present evidence
A controlled, non-production development programme and two closed public funding records.
Not presented as deployed, clinically validated, NHS-backed or production-ready.
Discovery and predevelopment remain bounded until a narrow problem, governed route and documentary evidence justify the next gate.
A discovery thesis around applied intelligence and robotics, developed only where a narrow buyer problem and governed data route can be evidenced.
Present evidence
A defined discovery direction.
No customer, deployed product, revenue or partnership is claimed.
A predevelopment route that would use qualified external laboratories, CROs and CDMOs rather than implying owned facilities.
Present evidence
Programme planning and diligence themes.
No site control, laboratory, manufacturing, pipeline ownership or regulated activity is claimed.
Exploratory and long-term theses describe research questions and venture intent. They do not imply operating companies, missions, facilities or partnerships.
A research thesis for ground-based evidence qualification before any space or extreme-environment deployment.
Present evidence
Exploratory research questions.
No mission, payload, partner, flight heritage or clinical capability is claimed.
Long-horizon concepts spanning technical softgoods, cultural design and new ways of describing time for lunar and planetary contexts.
Present evidence
Named venture theses within Varun’s 2030 vision.
They are not presented as operating companies, products, partnerships or missions.
The future stays credible when the rules for reaching it are visible.
A claim should survive a sceptical reader, a source check and the passage of time.
Software may organise evidence and options; accountable people retain judgement and approval.
NEUVIOR and PHARMORIS come first. Future theses advance only when evidence earns the next gate.
Unknown remains unknown. Uncertainty is not a branding flaw. Making it visible protects decisions, partners and reputation.